D e s i g n
Randomized {allocation concealed*}, † blinded (patients, outcome assessors, and study personnel),* placebo-controlled trial with median follow-up of 5.1 years (Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial [VA-HIT]).
S e t t i n g
20 Veterans Affairs medical centers in the United States.
P a t i e n t s
2531 men who were < 74 years of age (mean age 64 y); had a documented history of CAD; had no serious comorbid conditions; and had an HDL cholesterol level ≤ 40 mg/dL (1.0 mmol/L), an LDL cholesterol level ≤ 140 mg/dL (3.6 mmol/L), and a triglyceride level ≤ 300 mg/dL (3.4 mmol/L).
I n t e r v e n t i o n 1264 men were allocated to gemfibrozil, 1200 mg/d, and 1267 were allocated to placebo.
M a i n o u t c o m e m e a s u r e s
The main outcome was combined incidence of nonfatal myocardial infarction (MI) or death from CAD. Secondary outcomes included stroke and all-cause mortality.
M a i n r e s u l t s
Analysis was by intention to treat. Patients in the gemfibrozil group had a lower risk for the combined end point of nonfatal MI or CAD death and for investigator-designated stroke (Table) than did patients in the placebo group; groups did not differ for allcause mortality (15.7% vs 17.4%, P = 0.23).
C o n c l u s i o n
Among men with coronary artery disease and low levels of both high-density and low-density lipoprotein cholesterol, gemfibrozil reduced the risk for the combined end point of nonfatal myocardial infarction or death from coronary artery disease. 
C o m m e n t a r y
The results of the VA-HIT should change practice. Clinicians should no longer be complacent when patients with coronary disease have low HDL cholesterol levels (≤ 40 mg/dL) as well as LDL cholesterol levels below guideline-recommended thresholds for treatment. Women with lipid profiles similar to the men in this study should also benefit from treatment. The failure to show a reduction in all-cause mortality is not an important weakness; the sample size was not calculated to show this reduction. A larger study would probably show this reduction, as have other studies of cholesterollowering therapies. An alternative strategy for this patient population is the use of statins to lower LDL cholesterol levels to 70 to 80 mg/dL. In a small study of 341 patients, Pitt and colleagues (1) found that patients who had LDL cholesterol levels reduced to a mean of 77 mg/dL from about 145 mg/dL with atorvastatin had fewer ischemic events than patients treated with angioplasty and standard lipid management. The Scandinavian Simvastatin Survival Study showed a treatment benefit in patients with baseline LDL cholesterol levels of approximately 140 mg/dL; notably, HDL cholesterol levels increased 8% with simvastatin (2). Whether similar benefits from statins would be found in patients with LDL cholesterol levels of approximately 110 mg/dL-the mean level in VA-HIT patients-is unknown.
When treating patients with CAD who have normal LDL and low HDL cholesterol levels, evidence for using gemfibrozil is now stronger than for using statins. If a statin is used, clinicians should check for an increase in HDL cholesterol level of ≥ 6%, as seen in the VA-HIT. An alternative to medication might be weight loss and exercise if an equivalent 6% increase in HDL cholesterol levels can be achieved.
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